Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 2,572 shares of Class A Common Stock on July 28, 2025, at a price of $58.70, for a total value of $150,976.
Following the transaction, Boughton directly owns 155,593 shares of Hims & Hers Health, Inc.
The sale was executed under a Rule 10b5-1 trading plan adopted on August 28, 2024. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.
In other recent news, Hims & Hers Health reported that customers using its compounded GLP-1 weight loss treatments experienced an average weight loss of 10.3% over six months. The company highlighted a retention rate of 75% among customers, significantly better than the typical dropout rates for commercially available GLP-1 treatments. Meanwhile, BofA Securities maintained its Underperform rating for Hims & Hers, expressing concerns about potential litigation risks and pressure on the company’s full-year guidance due to mixed business prospects. Additionally, Morgan Stanley (NYSE:MS) reiterated an Equalweight rating, noting a decline in app downloads and citing slowing growth as a concern. The company also announced plans to expand into Canada by 2026, intending to offer generic semaglutide following Novo Nordisk (NYSE:NVO)’s loss of patent protection there. In a related development, Hims & Hers CEO Andrew Dudum disclosed details about the termination of a partnership with Novo Nordisk, which ended following disagreements over the continued offering of compounded semaglutide. These recent developments provide insight into the company’s current challenges and strategic directions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.